Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories established Pharmaceuticals — Segment Research & Development Expense ($M) ($M)
Form 10-K / 10-Q Segment Footnote
Latest, FY2025
176
Period ended Dec 31, 2025
Change on a year earlier
0.0%
176 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Established Pharmaceuticals — Segment Research & Development Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 176 | 0.0% | SEC Filing (0001628280-26-010185) ↗ |
| FY2024 | Dec 31, 2024 | 176 | +1.7% | SEC Filing (0001628280-26-010185) ↗ |
| FY2023 | Dec 31, 2023 | 173 | -7.0% | SEC Filing (0001628280-26-010185) ↗ |
| FY2022 | Dec 31, 2022 | 186 | – | SEC Filing (0001628280-25-007110) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Established Pharmaceuticals — Segment Research & Development Expense ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/epd-rd-exp
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.